SEARCH

SEARCH BY CITATION

References

  • ARIANO, M.A. & SIBLEY, D.R. (1994). Dopamine receptor distribution in the rat CNS; elucidation using anti-peptide antisera directed against the D1A and D3 subtypes. Brain Res., 649, 95110.
  • BOWEN, W.P., COLDWELL, M.C., HICKS, F.R. & RILEY, G.J. (1993). Further characterisation of human D2 and D3 receptors–GppNHp shifts are explained by the presence of more than one binding site in each clone. Br. J. Pharmacol., 108, 277P.
  • BOWEN, W.P. & JERMAN, J.C. (1995). Nonlinear regression using spreadsheets. Trends Pharm. Sci., 16, 413417.
  • BOYFIELD, I., WINN, F. & COLDWELL, M.C. (1996). Comparison of agonists potencies at human D2 and D3 receptors, expressed in the same cell line, using the Cytosensor Microphysiometer. Biochem. Soc. Trans., 24, 57S.
  • BURRIS, K.D., PACHECO, M.A., FILTZ, T.M., KUNG, M.-P., KUNG, H.F. & MOLINOFF, P.B. (1995). Lack of discrimination by agonists for D2 and D3 dopamine receptors. Neuropsychopharmacology, 12, 335345.
  • CAMACHO-OCHOA, M., WALKER, E.L., EVANS, D.L. & PIERCEY, M.F. (1995). Rat brain binding sites for pramipexole, a clinically useful D3-preferring agonist. Neurosci. Lett., 196, 97100.
  • CEDARBAUM, J.M., GANDY, S.E. & MCDOWELL, F.H. (1991). ‘Early’ initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias or dementia in Parkinson's Disease. Neurology, 41, 622629.
  • COLDWELL, M.C., BOYFIELD, I., BROWN, A.M., STEMP, G. & MIDDLEMISS, D.N. (1999). Pharmacological characterisation of extracellular acidification rate responses in human D2(long), D3 and D4.4 receptors separately expressed in Chinese hamster ovary cells, as measured by the Cytosensor microphysiometer. Br. J. Pharmacol., (in press).
  • DIAZ, J., LEVESQUE, D., LAMMERS, C.H., GRIFFON, N., MARTRES, M.-P., SCHWARZ, J.-C. & SOKOLOFF, P. (1995). Phenotypical characterization of neurones expressing the dopamine D3 receptor in rat brain. Neuroscience, 65, 731745.
  • DOMINO, E.F., LISONG, N., HUILEI, Z. & YASUKO, K. (1998). Effects of talipexole on contraversive rotation and functional impairment in MPTP-induced chronic hemiparkinsonian monkeys. Jap. J. Pharm., 77, 227233.
  • EDEN, R.J., COSTALL, B., DOMENY, A.M., GERRARD, P.A., HARVEY, C.A., KELLY, M.E., NAYLOR, R.J., OWEN, D.A. & WRIGHT, A. (1991). Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol. Biochem. Behav., 38, 147154.
  • GOETZ, G.G. & DIEDERICH, N.J. (1992). Dopaminergic agonists in the treatment of Parkinson's Disease. Neurologic Clinics, 10, 527540.
  • GONZALEZ, A.M. & SIBLEY, D.R. (1995). [3H]7-OH-DPAT is capable of labeling dopamine D2 as well as D3 receptors. Eur. J. Pharmacol., 272, R1R3.
  • HAGAN, J.J., MIDDLEMISS, D.N., SHARPE, P.C. & POSTE, G.H. (1997). Parkinson's Disease: prospects for improved drug therapy. Trends Pharm. Sci., 18, 156163.
  • HALL, H., HALLDIN, C., DIJKSTRA, D., WIKSTROM, H., WISE, L.D., PUGSLEY, T.A., SOKOLOFF, P., PAULI, S., FARDE, L. & SEDVALL, G. (1996). Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-receptor agonist (+)-[3H]PD 128907. Psychopharmacology, 128, 240247.
  • HERROELEN, L., DE BACKER, J.P., WILCZAK, N., FLAMEZ, A., VAUQUELIN, G. & DE KEYSER, J. (1994). Autoradiographic distribution of D3-type dopamine receptors in human brain using 7-[3H]hydroxy-N,N-di-n-propyl-l-aminotetralin. Brain Res., 648, 222228.
  • HURLEY, M.J., JOLKKONEN, J., STUBBS, C.M., JENNER, P. & MARSDEN, C.D. (1996). Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment. Brain Res., 709, 259264.
  • JENNER, P. & TULLOCH, I. (1997). In, Beyond the decade of the Brain, vol 2. Dopamine Agonists in early Parkinson's Disease. Ed. Olanow, C.W. & Obeso J.A. Wells Medical Ltd.
  • KORCZYN, A.D., BROOKS, D.J., BRUNT, E.R., POEWE, W.H., RASCOL, O. & STOCCHI, F. (1998). Ropinirole versus bromocriptine in the treatment of early Parkinson's Disease: a 6 month interim report of a 3-year study. Movement Disorders, 13, 4651.
  • LESSER, R.P., FAHN, S., SNIDER, S.R., COTE, L.J., ISGREEN, W.P. & BARRET, R.E. (1979). Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology, 29, 12531260.
  • LEVESQUE, D., DIAZ, J., PILON, C., MATRES, M.-P., GIROS, B., SOUIL, E., SCHOTT, D., MORGAT, J.-L., SCHWARTZ, J.-C. & SOKOLFF, P. (1992). Identification, characterisation and localisation of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-l-aminotetralin. Proc. Natl Acad. Sci. U.S.A., 89, 81558159.
  • LIEBERMAN, A.N. & GOLDSTEIN, M. (1985). Bromocriptine in Parkinson's Disease. Pharmacol. Rev., 37, 217227.
  • MARSDEN, C.D. & PARKES, J.D. (1977). Success and problems of long-term levodopa therapy in Parkinson's Disease. Lancet, i, 345349.
  • MCCONNELL, H.M., OWICKI, J.C., PARCE, J.W., MILLER, D.L., BAXTER, G.T., WADA, H.G. & PITCHFORD, S. (1992). The Cytosensor microphysiometer: biological applications of silicon technology. Science, 257, 10961912.
  • MIERAU, J. (1995). Pramipexole: a dopamine-receptor agonist for treatment of Parkinson's Disease. Clini. Neuropharm., 18, S195S206.
  • MIERAU, J., SCHNEIDER, F.J., ENSINGER, H.A., CHIO, C.L., LAJINESS, M.E. & HUFF, R.M. (1995). Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur. J. Pharmacol., 290, 2936.
  • MIZUNO, Y., KOWA, H., NAKANISHI, T. & YANAGISAWA, N. (1993). Preliminary study of B-HT 920, a novel dopamine agonist, for the treatment of Parkinson's Disease. Drug Investigation, 5, 186192.
  • MOLHO, E.S., FACTOR, S.A., WEINER, W.J., SANCHEZ-RAMOS, J.R., SINGER, C., SHULMAN, L., BROWN, D. & SHELDON, C. (1995). The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's Disease. J. Neural. Transm., 45, (Suppl): 225230.
  • MURRAY, A.M., RYOO, H.L., GUREVICH, E. & JOYCE, J.N. (1994). Localisation of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc. Natl. Acad. Sci. U.S.A., 91, 1127111275.
  • OWICKI, J.C., PARCE, J.W., KERSCO, K.M., SIGAL, G.B., WADA, H.G., MIUR, V.C., BOUSSE, L.J., ROSS, K.L. & MCCONNELL, H.M. (1990). Continuous monitoring of receptor mediated changes in metabolic rates in living cells. Proc. Nat. Acad. Sci. U.S.A., 87, 40074011.
  • RABEY, J.M. (1995). Second generation of dopamine agonists – Pros and Cons. J. Neural. Trans., 45, 213224.
  • RINNE, U.K. (1989). Lisuride, a dopamine agonist in treatment of early Parkinson's Disease. Neurology, 39, 336339.
  • SAGE, J.I. & MARK, M.H. (1994). Basic mechanisms of motor fluctuations. Neurology, 44, (suppl 6): S10S14.
  • SAUTEL, F., GRIFFON, N., LEVESQUE, D., PILON, C. SCHWARTZ, J.-C. & SOKOLOFF, P. (1995). A functional test identifies dopamine agonists selective for D3 versus D2 receptors. Neuroreport, 6, 329332.
  • SELBIE, L.A., HAYES, G. & SHINE, J. (1989). The major dopamine D2 receptor: molecular analysis of the human D2A subtype. DNA, 8, 683689.
  • SETHI, K.D., O'BRIEN, C.F., HAMMERSTAD, J.P., ADLER, C.H. DAVIS, T.L., TAYLOR, R.L., SANCHEZ-RAMOS, J., BERTONI, J.M. & HAUSER, R.A. (1998). Ropinirole for the treatment of early Parkinson Disease. Arch. Neurol., 55, 12111216.
  • SOKOLOFF, P., GIROS, B., MARTRES, M.P., BOUTHENET, M.L. & SCHWARTZ, J.C. (1990). Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature, 347, 146151.
  • SOKOLOFF, P. & SCWARTZ, J.-C. (1995). Novel DA receptors half a decade later. Trends Pharmacol. Sci., 16, 270275.
  • TILFORD, N.S., BOWEN, W.P. & BAXTER, G.S. (1995). Robofit: a versatile macro-driven template for curve fitting, analysis and presentation in Microsoft Excel. Br. J. Pharmacol., 115, 160P.
  • TULLOCH, I.F. (1997). Pharmocologic profile of ropinirole. Neurology, 49, (Suppl 1): S58S62.